DailyIQ
|
Sector:HealthcareAll sectors
Last updated 100 days ago

BIO·BIO

$.
-. (-.%)
After Hours
High
$272.79
Open
$251.00
Market Cap
6.92B
52W High
$343.12
Low
$246.00
P. Close
$292.42
P/E
-
52W Low
$211.43
Fwd P/E
-
Mean Target
-
Technical Score (1D)
9
SELL
News Sentiment
57
BULLISH
Bio-Rad Laboratories (BIO) returned to profitability in Q4 2025, a development fueled by the Diagnostics segment's rebound and the success of the ddPCR portfolio. This shift could alter the investment outlook for BIO, as the company demonstrated positive full-year sales despite margin pressures and an impairment charge. The Diagnostics segment's growth and the ddPCR portfolio's traction are key to watch in the coming days, as sustained performance in these areas will be critical for maintaining profitability. Investors should monitor how BIO manages its costs and the impact of the impairment charge on future earnings.
Earnings Summary
Bio-Rad Laboratories, Inc. is a healthcare company operating in the medical devices industry, manufacturing and distributing life science research and clinical diagnostic products. The company's products are used in various applications, including biopharmaceutical manufacturing and clinical diagnostics. In the broader healthcare sector, Bio-Rad competes with other medical device companies. In Q4 2025, Bio-Rad's revenue was $693.2 million, with an EPS of $2.51, compared to Q4 2024, where revenue was $667.5 million with an EPS of $2.9. The company's Q1 2026 EPS and revenue are not available. Bio-Rad beat estimates in one of the two quarters where EPS data is available. The company's Q4 2025 revenue increased, but the EPS decreased. The company's Q4 2025 revenue increased by 3.9%, and the full-year 2025 saw modest revenue growth. The company's Q4 2025 adjusted earnings per share were $2.51 on revenue of $693.2 million. Recent news indicates that Bio-Rad's Diagnostics segment showed growth, which partially offset weakness in Life Science sales, and management is focused on operational improvements. Investors should watch for the company's progress in improving operational efficiency and the performance of its Life Science segment. The market will also be watching for any further details on the company's 2026 outlook.

EPS

EstBeatMiss
$1.74$2.07$2.40$2.72$3.05Q4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$2.00$1.89-5.7%
Q4'25$2.47$2.51+1.7%
Q4'24$2.88$2.90+0.6%

Revenue

EstBeatMiss
$577M$610M$643M$676M$708MQ4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$595M$592M-0.4%
Q4'25$600M$693M+15.6%
Q4'24 - $668M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BIO Stock Snapshot

BIO is currently trading at $256.56, giving BIO a market cap of 6.92B. Today's range spans $246.00–$272.79, with shares opening at $251.00 and moving down $35.86 (12.3%) from the prior close. DailyIQ's technical score sits at 9/100 (SELL) with a news sentiment reading of 57/100.

Over the past year BIO has traded between $211.43 and $343.12 - the current price is +21.3% off the 52-week low and -25.2% from the high.

BIO is a small-cap Healthcare stock (6.92B market cap) in a non-trending phase. Score: 9/100 (SELL). Sentiment: neutral (57/100). Price: $256.56 (in the lower half of its 52-week range in $211.43–$343.12). At this capitalization tier, SELL signals combined with neutral news flow often indicate a period of institutional disinterest - the setup can stay neutral or deteriorate until a catalyst restores conviction.

The absence of strong institutional sponsorship makes BIO's SELL signal (9/100) more consequential than the same signal in a larger name — at 6.92B in Healthcare market cap, there are fewer natural buyers to absorb selling pressure, which means the $211.43–$343.12 range's lower bound becomes a sharper test of the thesis. Sentiment at 57/100 (neutral) and price at $256.56 (in the lower half of its 52-week range) don't yet suggest stabilization is imminent.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…